Furthermore, among the secondary outcomes at 1 month, HF-related hospitalization and stroke were significantly lower in the SGLT2 inhibitor users compared to non-users [1 (0.3%) vs. 9 (8%), p-value < 0.001; 1 (0.3%) vs. 3 (2.7%), p-value = 0.045, respectively]. The gene discussed is SLC5A2; the disease is hydrops fetalis.